Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

México Noticias Noticias

Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA
México Últimas Noticias,México Titulares
  • 📰 CNBC
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 72%

'It's a complete coin flip that will now be in the hands of the FDA,' says Jared Holz, a health-care strategist at Jefferies.

The Cambridge, Massachusetts-based company still faces an uphill battle with the federal regulator, however.

"It's a complete coin flip that will now be in the hands of the FDA," said Jared Holz, a health-care strategist at Jefferies, who put the chances of regulatory approval at 60%.The FDA will be under immense pressure from advocacy groups, patients and families living with the disease to approve the drug when Biogen submits it to regulators, likely in early 2020.

Aducanumab targets a "sticky" compound in the brain known as beta-amyloid, which is hypothesized to play a role in the devastating disease. More research is needed on the compound, and not all scientists are convinced that beta-amyloid is the primary cause of Alzheimer's. Many clinical trials targeting the compound have ended in failure.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

CNBC /  🏆 12. in US

México Últimas Noticias, México Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Biogen Details Case for Controversial Alzheimer’s DrugBiogen Details Case for Controversial Alzheimer’s DrugBiogen tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.
Leer más »

Patients, companies cheer as FDA speedily green-lights drugs. Others are alarmedPatients, companies cheer as FDA speedily green-lights drugs. Others are alarmedThe U.S. is approving new drugs so fast that companies are preparing for a green light months ahead of the scheduled decision date.
Leer más »

Biogen Details Case for Controversial Alzheimer’s DrugBiogen Details Case for Controversial Alzheimer’s DrugBiogen tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.
Leer más »

https://time.comhttps://time.comBreaking news and analysis from TIME.com. Politics, world news, photos, video, tech reviews, health, science and entertainment news.
Leer más »

R. Kelly Accused of Bribing Official Day Before Marrying AaliyahR. Kelly Accused of Bribing Official Day Before Marrying AaliyahR. Kelly faces new charges for bribery potentially involving his illegal marriage to Aaliyah
Leer más »

New details emerge on drug that may slow Alzheimer’s diseaseNew details emerge on drug that may slow Alzheimer’s diseaseExcitement and skepticism have surrounded the drug since its developers stopped studies earlier this year because it didn't seem to be working.
Leer más »



Render Time: 2025-04-01 03:42:36